Section Editor: Gerald L. Andriole, Jr., MD

Cancer diagnosis and therapy is becoming more focused toward a patient-specific approach to therapy, particularly prostate cancer. The role of imaging is paramount in this evolution by providing physicians with accurate information on both the presence and extent of prostate cancers. Developments in molecular imaging are paving the way for more physicians to diagnose cancer and apply relevant therapy. Various imaging modalities and methods may be best suited for different phases of the disease. Our associated physicians discuss the importance of imaging in more detail below.


Incorporating New PET Imaging and Theranostic Approaches into Prostate Cancer Practice

Phillip J. Koo, MD, chair of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), discusses advances in nuclear medicine and imaging, basic concepts of the theranostic approach, and controversies in this field. Following Dr. Koo’s discussion of the current state of nuclear medicine, Susan F. Slovin, MD, PhD, discusses the three iterations of the Radiographic Assessments for Detection of Advanced Recurrence (RADAR).





Drs. Albala, Crawford & Koo - AUA PSMA PET Abstracts

PSMA PET for Improving the Diagnosis, Treatment, and Management of Prostate Cancer – AUA Abstract Review

E. David Crawford, MD, Philip J. Koo, MD, and David M. Albala, MD, present seven abstracts highlighting PMSA PET imaging and its impact on prostate cancer management.

Panel Discussion – Focus on PSMA

Phillip J. Koo, MD, leads a panel discussion focused on PSMA PET-CT’s expanding role in prostate cancer screening and diagnosis.

Urologic Perspective on the Clinical Utility of and Emerging Data on Micro-Ultrasound

Rafael Sanchez-Salas, MD, reviews data on micro-ultrasound for prostate cancer imaging and assesses its utility in comparison to MRI.

Radiologic Perspective on the Clinical Utility of and Emerging Data on Micro-Ultrasound

Sangeet Ghai, MD, FRCR, reviews data on micro-ultrasound for PCa imaging and assesses whether it is superior to conventional imaging.

Emerging Role of PSMA Imaging

Steven P. Rowe, MD, PhD, explains research supporting the emerging role of PSMA imaging in prostate cancer diagnosis and therapy.

International Prostate Cancer Update 2021 Session Review: Next Generation Imaging – Focus on PSMA

Phillip J. Koo, MD, summarizes talks from a session he moderated on next generation imaging, with a focus on PSMA, during IPCU 31.

Next Generation Imaging for Localization of Recurrent Prostate Cancer

Brian T. Helfand, MD, PhD, discusses the efficacy of next generation imaging options for localization of recurrent prostate cancer.

Recent Advancements in PI-RADS: mpMRI vs. bpMRI

Jelle Barentsz, MD, PhD, discusses recent advancements in PI-RADS and comparative studies of mpMRI and bpMRI.

Integrating Theranostics Into a Group Practice

David M. Albala, MD, discusses theranostics and considers its future role as a form of precision medicine for prostate cancer.

Treatment for Prostate Cancer with MRI-Guided Transurethral Ultrasound

Laurence Klotz, MD, FRCSC, makes a case for MRI-guided transurethral ultrasound ablation (TULSA) in patients with localized prostate cancer.

PSMA PET Imaging at Time of Diagnosis

Peter R. Carroll, MD, MPH, summarizes data on PSMA PET and compares its overall efficacy to conventional imaging at the time of diagnosis.

Radiation Oncology Perspective: Image-Guided Metastasis-Directed Therapy

Steven E. Finkelstein, MD, FACRO, discusses 3 cases of prostate cancer recurrence and their clinical management from a radiation oncology perspective.


Gerald L. Andriole, Jr., MD
Johns Hopkins Medicine
Washington, DC

Gerald L. Andriole, Jr., MD, is Director of Urology in the National Capital Region at the Brady Urologic Institute at Johns Hopkins University. He formerly served as the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center, and Washington University School of Medicine in St. Louis, Missouri. Dr. Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. He trained in surgery at Strong Memorial Hospital and the University of Rochester and completed his Urology Residency at Brigham and Women’s Hospital and Harvard Medical School. Subsequently, he was a Fellow in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland. Dr. Andriole has over 35 years of consistent contributions in the areas of BPH and prostate cancer screening and prevention research. He has contributed well over 400 peer-reviewed publications and serves on the editorial boards of several prestigious journals. He is Chairman of the Prostate Committee of the National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, and PI of the NIDDK Multidisciplinary Approach to Urologic Pelvic Pain (MAPP) and Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN). He was Chairman of the Steering Committee of the REDUCE Prostate Cancer Prevention Trial, as well as PI of both the NIDDK Medical Therapy of Prostatic Symptoms (MTOPS) BPH trial and the NIDDK Complementary and Alternative Medicine for Urinary Symptoms (CAMUS) study. He is a member of the American Urological Association, the American Association for Cancer Research, the American Society of Clinical Oncology, the American Surgical Association, the American Association of Genitourinary Surgeons, and the Clinical Society of Genitourinary Surgeons, among other societies.

Supported in part by Blue Earth Diagnostics, Inc.